Anakinra in Dengue With Hyperinflammation ( AnaDen )
Dengue, Dengue With Warning Signs, Severe Dengue
About this trial
This is an interventional treatment trial for Dengue focused on measuring Dengue, Hyperinflammatory syndrome, Anakinra, Vietnam
Eligibility Criteria
Inclusion Criteria: Patients hospitalised with a clinical diagnosis of dengue and at least 1 warning sign(s) (see appendix) or severe dengue to Emergency department/inpatient wards/Intensive Care wards (ICU), Ferritin levels > 2000ng/mL ≥ 12 years of age Written informed consent or assent to participate in the study Agree to come back for 2 follow up visits around day 30 of illness (maximum 5 weeks) and at 3 months Exclusion Criteria: Pregnancy Localizing features suggesting an alternative/additional diagnosis, e.g. pneumonia, sepsis Patients taking immunosuppressive drugs or other biologics in last 1 month Patients with underlying malignancy or immunosuppression Children <12 years Have end-stage renal failure (baseline GFR < 30ml/min) Being treated for TB Taking any drug with significant interaction with anakinra The study physician judges that the patient is unlikely to attend follow up visit at around 3-4 weeks after fever onset - e.g. due to long travelling distance from the clinic
Sites / Locations
- Hospital for Tropical Diseases
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Anakinra
The control group will be formed of 80 dengue patients with warning signs or severe dengue receiving placebo.
The intervention group will include 80 dengue patients with warning signs or severe dengue receiving anakinra.